⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SABS News
SAB Biotherapeutics, Inc. Common Stock
Form 8-K
sec.gov
SABS
SABSW
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
globenewswire.com
SABS
Form 8-K
sec.gov
SABS
SABSW
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
globenewswire.com
SABS
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
globenewswire.com
SABS
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
globenewswire.com
SABS
Form 8-K
sec.gov
SABSW
SABS
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
globenewswire.com
SABS
EBS
Form 8-K
sec.gov
SABS
SABSW
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026
globenewswire.com
SABS
SABSW